<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Hepatol</journal-id><journal-id journal-id-type="publisher-id">WJH</journal-id><journal-title-group><journal-title>World Journal of Hepatology</journal-title></journal-title-group><issn pub-type="epub">1948-5182</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6206158</article-id><article-id pub-id-type="pmid">30386459</article-id><article-id pub-id-type="other">jWJH.v10.i10.pg662</article-id><article-id pub-id-type="doi">10.4254/wjh.v10.i10.662</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="84248" pm="."><plain>Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Cheng-Jie</given-names></name><aff>Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China</aff></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Zhi-Gao</given-names></name><aff>Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China</aff></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Guan-Dou</given-names></name><aff>Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China</aff></contrib><contrib contrib-type="author"><name><surname>Lei</surname><given-names>Biao</given-names></name><aff>Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China</aff></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Song-Qing</given-names></name><aff>Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi Zhuang Autonomous Region, China. <email>dr_hesongqing@163.com</email></aff></contrib></contrib-group><author-notes><fn><p><text><SENT sid="84249" pm="."><plain>Author contributions: Lin CJ and Hu ZG contributed equally to this work; He SQ designed research; Lin CJ, Hu ZG and Yuan GD searched the relevant literatures; and Lin CJ wrote the review; Lei B and He SQ revised the review. </plain></SENT>
</text></p><p><text><SENT sid="84250" pm="."><plain>Supported by State Key Program of National Natural Science Foundation of China, No. 8143000311; National Natural Science Foundation of China, No. 81660103 and No. 81771674; 111 Project, No. D17011; Guangxi BaGui Scholars; the Natural Science Foundation of Guangxi Province, No. 2015GXNSFFA139004. </plain></SENT>
</text></p><p><text><SENT sid="84251" pm="."><plain>Correspondence to: Song-Qing He, PhD, Chief Doctor, Professor, Research Professor, Department of Hepatopancreatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning 530021, Guangxi Zhuang Autonomous Region, China. dr_hesongqing@163.com </plain></SENT>
</text></p><p><text><SENT sid="84252" pm="."><plain>Telephone: +86-771-5356568 </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><day>27</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>27</day><month>10</month><year>2018</year></pub-date><volume>10</volume><issue>10</issue><fpage>662</fpage><lpage>669</lpage><history><date date-type="received"><day>10</day><month>4</month><year>2018</year></date><date date-type="rev-recd"><day>26</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>1</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="84253" pm="."><plain>The complement system is a key component of the body’s immune system. </plain></SENT>
<SENT sid="84254" pm="."><plain>When abnormally activated, this system can induce inflammation and damage to normal tissues and participate in the development and progression of a variety of diseases. </plain></SENT>
<SENT sid="84255" pm="."><plain>In the past, many scholars believed that alcoholic liver disease (ALD) is induced by the stress of ethanol on liver cells, including oxidative stress and dysfunction of mitochondria and protease bodies, causing hepatocyte injury and apoptosis. </plain></SENT>
<SENT sid="84256" pm="."><plain>Recent studies have shown that complement activation is also involved in the genesis and development of ALD. </plain></SENT>
<SENT sid="84257" pm="."><plain>This review focuses on the roles of complement activation in ALD and of therapeutic intervention in complement-activation pathways. </plain></SENT>
<SENT sid="84258" pm="."><plain>We intend to provide new ideas on the diagnosis and treatment of ALD. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>Alcoholic liver disease</kwd><kwd>Complement system proteins</kwd><kwd>Complement regulator</kwd><kwd>Liver cells</kwd><kwd>Hepatocyte injury</kwd></kwd-group></SecTag></article-meta></front><body><p><text><SENT sid="84259" pm="."><plain>Core tip: In this review, we cited evidence that the complement system is involved in the pathogenesis of each stage of alcoholic liver disease (ALD) that include fatty liver, alcoholic hepatitis, and fibrosis/cirrhosis, and we also summarized the complement regulation in ALD. </plain></SENT>
<SENT sid="84260" pm="."><plain>We intend to provide new ideas on the treatment of ALD. </plain></SENT>
</text></p><SecTag type="INTRO"><sec><title><text><SENT sid="84261" pm="."><plain>INTRODUCTION </plain></SENT>
</text></title><p><text><SENT sid="84262" pm="."><plain>Liver disease caused by long-term excessive ethanol drinking is a major cause of chronic liver disease. </plain></SENT>
<SENT sid="84263" pm="."><plain>As the global incidence of alcoholic liver disease (ALD) increases year by year, it has become a serious threat to human health. </plain></SENT>
<SENT sid="84264" pm="."><plain>Almost all heavy drinkers have fatty liver, 10%-20% of which develop into alcoholic hepatitis, cirrhosis, and even hepatocellular carcinoma[1]. </plain></SENT>
<SENT sid="84265" pm="."><plain>Exploration of the mechanisms of alcohol-induced liver injury and repair is extremely important in developing methods for preventing and treating ALD. </plain></SENT>
</text></p><p><text><SENT sid="84266" pm="."><plain>The complement system plays an important beneficial role in the immune system: Complement activation promotes target-cell lysis, with the associated elimination of exogenous pathogens. </plain></SENT>
<SENT sid="84267" pm="."><plain>Yet, the complement system is a “double-edged sword”, as the excessive activation of complement can induce inflammation and lead to autoimmune diseases, such as autoimmune kidney disease, glomerular nephritis, acute lung injury, and others[2-5]. </plain></SENT>
<SENT sid="84268" pm="."><plain>Most plasma complement components are synthesized in liver cells. </plain></SENT>
<SENT sid="84269" pm="."><plain>Thus, the liver becomes the main target of damage by complement activation[6-8]. </plain></SENT>
<SENT sid="84270" pm="."><plain>This connection is likely due to the direct effects of alcohol that activate complement, but not because the liver is a major producer of complement proteins. </plain></SENT>
<SENT sid="84271" pm="."><plain>Several studies have illustrated that complement activation is involved in the development of ALD[8-14] (Table 1). </plain></SENT>
</text></p><SecTag type="TABLE"></SecTag><p><text><SENT sid="84422" pm="."><plain>Specific epitope structures of complement, such as anti-complement antibody, complement antisense strand, and complement mutants[84-91] have been invented, with the intent of inhibiting complement activation. </plain></SENT>
<SENT sid="84423" pm="."><plain>In addition, complement inhibitors and RNA aptamer are being used to inhibit progression of complement-related diseases[92,93], and C1-INH and CR1 have been used in the treatment of ALD and other diseases[10]. </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec><title><text><SENT sid="84424" pm="."><plain>CONCLUSION </plain></SENT>
</text></title><p><text><SENT sid="84425" pm="."><plain>Mounting evidence indicates that complement activation is involved in the development of ALD at all its stages - fatty liver, alcoholic hepatitis, and fibrosis/cirrhosis. </plain></SENT>
<SENT sid="84426" pm="."><plain>Moreover, all three pathways of complement activation (classical, MBL, and alternative) promote the development of ALD. </plain></SENT>
<SENT sid="84427" pm="."><plain>Therapeutic strategies, using various measures to inhibit complement activation, might prevent the development of ALD. </plain></SENT>
<SENT sid="84428" pm="."><plain>Thorough understanding of the relationships between complement activation and ALD may aid in developing new approaches for the treatment of ALD. </plain></SENT>
</text></p></sec></SecTag></body><back><fn-group><fn fn-type="COI-statement"><p><text><SENT sid="84429" pm="."><plain>Conflict-of-interest statement: All authors have no conflicts of interest to report. </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84430" pm="."><plain>Manuscript source: Invited manuscript </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84431" pm="."><plain>Peer-review started: April 10, 2018 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84432" pm="."><plain>First decision: May 17, 2018 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84433" pm="."><plain>Article in press: August 1, 2018 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84434" pm="."><plain>Specialty type: Gastroenterology and hepatology </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84435" pm="."><plain>Country of origin: China </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84436" pm="."><plain>Peer-review report classification </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84437" pm="."><plain>Grade A (Excellent): 0 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84438" pm="."><plain>Grade B (Very good): 0 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84439" pm="."><plain>Grade C (Good): C, C, C, C </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84440" pm="."><plain>Grade D (Fair): 0 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84441" pm="."><plain>Grade E (Poor): 0 </plain></SENT>
</text></p></fn><fn><p><text><SENT sid="84442" pm="."><plain>P- Reviewer: Marcos M, Metin U, Morales-González JA, Kollmann D S- Editor: Ma YJ L- Editor: Ma JY E- Editor: Bian YN </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="84443" pm="."><plain>1WarrenKRMurrayMMAlcoholic liver disease and pancreatitis: global health problems being addressed by the US National Institute on Alcohol Abuse and AlcoholismJ Gastroenterol Hepatol201328 Suppl 146 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="84444" pm="."><plain>2YangYMannose Binding Lectin and kidney diseaseInt J Nephrol Urol201030241244 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="84445" pm="."><plain>3BorzaDBGlomerular basement membrane heparan sulfate in health and disease: A regulator of local complement activationMatrix Biol201757-5829931027609404 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="84446" pm="."><plain>4RusskampNFRuemmlerRRoeweJMooreBBWardPABosmannMExperimental design of complement component 5a-induced acute lung injury (C5a-ALI): a role of CC-chemokine receptor type 5 during immune activation by anaphylatoxinFASEB J2015293762377225999468 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="84447" pm="."><plain>5ReichhardtMPMeriSIntracellular complement activation-An alarm raising mechanism?Semin Immunol2018 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="84448" pm="."><plain>6ShenHFrenchBALiuHTillmanBCFrenchSWIncreased activity of the complement system in the liver of patients with alcoholic hepatitisExp Mol Pathol20149733834425217811 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="84449" pm="."><plain>7HeSAtkinsonCEvansZEllettJDSouthwoodMElvingtonAChavinKDTomlinsonSA role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injuryJ Immunol20091834764477219752222 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="84450" pm="."><plain>8PritchardMTMcMullenMRStavitskyABCohenJILinFEdward MedofMNagyLEDifferential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in miceGastroenterology20071321117112617383432 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="84451" pm="."><plain>9StewartSJonesDDayCPAlcoholic liver disease: new insights into mechanisms and preventative strategiesTrends Mol Med2001740841311530336 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="84452" pm="."><plain>10JärveläinenHAVäkeväALindrosKOMeriSActivation of complement components and reduced regulator expression in alcohol-induced liver injury in the ratClin Immunol2002105576312483994 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="84453" pm="."><plain>11BykovIJunnikkalaSPeknaMLindrosKOMeriSComplement C3 contributes to ethanol-induced liver steatosis in miceAnn Med20063828028616754259 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="84454" pm="."><plain>12CohenJIRoychowdhurySDiBelloPMJacobsenDWNagyLEExogenous thioredoxin prevents ethanol-induced oxidative damage and apoptosis in mouse liverHepatology2009491709171719205032 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="84455" pm="."><plain>13CohenJIRoychowdhurySMcMullenMRStavitskyABNagyLEComplement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in miceGastroenterology2010139664674, 674.e120416309 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="84456" pm="."><plain>14OrmanESOdenaGBatallerRAlcoholic liver disease: pathogenesis, management, and novel targets for therapyJ Gastroenterol Hepatol201328 Suppl 1778423855300 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="84457" pm="."><plain>15ZhaoJThe metabolism and harm of alcoholKeji &amp; Shenghuo20116195198 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="84458" pm="."><plain>16KawarataniHTsujimotoTDouharaATakayaHMoriyaKNamisakiTNoguchiRYoshijiHFujimotoMFukuiHThe effect of inflammatory cytokines in alcoholic liver diseaseMediators Inflamm2013201349515624385684 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="84459" pm="."><plain>17CohenJIChenXNagyLERedox signaling and the innate immune system in alcoholic liver diseaseAntioxid Redox Signal20111552353421126203 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="84460" pm="."><plain>18LeungTMNietoNCYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver diseaseJ Hepatol20135839539822940046 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="84461" pm="."><plain>19CohenJINagyLEPathogenesis of alcoholic liver disease: interactions between parenchymal and non-parenchymal cellsJ Dig Dis2011123921091930 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="84462" pm="."><plain>20NagyLEThe Role of Innate Immunity in Alcoholic Liver DiseaseAlcohol Res20153723725026695748 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="84463" pm="."><plain>21RicklinDHajishengallisGYangKLambrisJDComplement: a key system for immune surveillance and homeostasisNat Immunol20101178579720720586 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="84464" pm="."><plain>22QinXGaoBThe complement system in liver diseases. </plain></SENT>
<SENT sid="84465" pm="."><plain>Cell Mol Immunol20063333340 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="84466" pm="."><plain>23VieyraMBHeegerPSNovel aspects of complement in kidney injuryKidney Int20107749549920016462 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="84467" pm="."><plain>24HeWMedical immunology2010BeijingPeople’s Medical Publishing House7691 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="84468" pm="."><plain>25RoereckeMNanauRRehmJNeumanMEthnicity matters: A Systematic Review and Meta-Analysis of the Non-Linear Relationship Between Alcohol Consumption and Prevalence and Incidence of Hepatic SteatosisEBioMedicine2016831733027428441 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="84469" pm="."><plain>26LiuLZhaoXWangQSunXXiaLWangQYangBZhangYMontgomerySMengHProsteatotic and Protective Components in a Unique Model of Fatty Liver: Gut Microbiota and Suppressed Complement SystemSci Rep201663176327550859 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="84470" pm="."><plain>27WlazloNvan GreevenbroekMMFerreiraIJansenEHFeskensEJvan der KallenCJSchalkwijkCGBravenboerBStehouwerCDActivated complement factor 3 is associated with liver fat and liver enzymes: the CODAM studyEur J Clin Invest20134367968823586841 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="84471" pm="."><plain>28CopenhaverMYuCYHoffmanRPComplement Components, C3 and C4, and the Metabolic SyndromeCurr Diabetes Rev2018 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="84472" pm="."><plain>29GuptaARezvaniRLapointeMPoursharifiPMarceauPTiwariSTchernofACianfloneKDownregulation of complement C3 and C3aR expression in subcutaneous adipose tissue in obese womenPLoS One20149e9547824743347 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="84473" pm="."><plain>30MaslowskaMWangHWCianfloneKNovel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidenceVitam Horm20057030933215727809 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="84474" pm="."><plain>31KalantDPhélisSFieldingBAFraynKNCianfloneKSnidermanADIncreased postprandial fatty acid trapping in subcutaneous adipose tissue in obese womenJ Lipid Res2000411963196811108729 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="84475" pm="."><plain>32Bavia L, de Castro ÍA, Massironi SM, Isaac LBasal physiological parameters of two congenic mice strains: C5 deficient C57BL/6 and C5 sufficient A/JImmunol Lett2014159475424607390 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="84476" pm="."><plain>33Bavia L, de Castro ÍA, Isaac LC57BL/6 and A/J Mice Have Different Inflammatory Response and Liver Lipid Profile in Experimental Alcoholic Liver DiseaseMediators Inflamm2015201549164126448681 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="84477" pm="."><plain>34ShiWZhuQGuJLiuXLuLQianXShenJZhangFLiGAnti-IL-17 antibody improves hepatic steatosis by suppressing interleukin-17-related fatty acid synthesis and metabolismClin Dev Immunol2013201325304624396389 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="84478" pm="."><plain>35HuXWangYHaoLYLiuXLeschCASanchezBMWendlingJMMorganRWAicherTDCarterLLCorrigendum: Sterol metabolism controls TH17 differentiation by generating endogenous RORγ agonistsNat Chem Biol201511741 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="84479" pm="."><plain>36PaïdassiHTacnet-DelormePGarlattiVDarnaultCGhebrehiwetBGaboriaudCArlaudGJFrachetPC1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognitionJ Immunol20081802329233818250442 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="84480" pm="."><plain>37Lu JH, Teh BK, Wang Ld, Wang YN, Tan YS, Lai MC, Reid KBThe classical and regulatory functions of C1q in immunity and autoimmunityCell Mol Immunol2008592118318990 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="84481" pm="."><plain>38Bavia L, de Castro ÍA, Cogliati B, Dettoni JB, Alves VA, Isaac LComplement C5 controls liver lipid profile, promotes liver homeostasis and inflammation in C57BL/6 genetic backgroundImmunobiology201622182283226896155 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="84482" pm="."><plain>39PetrasekJBalaSCsakTLippaiDKodysKMenashyVBarrieauMMinSYKurt-JonesEASzaboGIL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in miceJ Clin Invest20121223476348922945633 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="84483" pm="."><plain>40MartinonFMayorATschoppJThe inflammasomes: guardians of the bodyAnnu Rev Immunol20092722926519302040 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="84484" pm="."><plain>41MacLarenRCuiWCianfloneKAdipokines and the immune system: an adipocentric viewAdv Exp Med Biol200863212119025110 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="84485" pm="."><plain>42JiangXLCohenJINagyLEPathogenesis of Alcoholic Liver Disease:Interactions between Parenchymal and Non-parenchymal CellsWeichangbing Xue201116131134 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="84486" pm="."><plain>43LeemingDJVeidalSSKarsdalMANielsenMJTrebickaJBuskTBendtsenFKragAMøllerSPro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosisScand J Gastroenterol20155058459225639675 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="84487" pm="."><plain>44JeongWIGaoBInnate immunity and alcoholic liver fibrosisJ Gastroenterol Hepatol200823 Suppl 1S112S11818336653 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="84488" pm="."><plain>45DuddempudiATImmunology in alcoholic liver diseaseClin Liver Dis20121668769823101977 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="84489" pm="."><plain>46BaumannMWitzkeOCanbayAPatschanSTreichelUGerkenGPhilippTKribbenASerum C3 complement concentrations correlate with liver function in patients with liver cirrhosisHepatogastroenterology2004511451145315362774 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="84490" pm="."><plain>47ChongWPToYFIpWKYuenMFPoonTPWongWHLaiCLLauYLMannose-binding lectin in chronic hepatitis B virus infectionHepatology2005421037104516231358 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="84491" pm="."><plain>48KarkampounaSTen DijkePDooleySJulioMKTGFβ signaling in liver regenerationCurr Pharm Des2012184103411322630085 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="84492" pm="."><plain>49HillebrandtSWasmuthHEWeiskirchenRHellerbrandCKeppelerHWerthASchirin-SokhanRWilkensGGeierALorenzenJComplement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humansNat Genet20053783584315995705 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="84493" pm="."><plain>50DeaciucIVFortunatoFD’SouzaNBHillDBMcClainCJChronic alcohol exposure of rats exacerbates apoptosis in hepatocytes and sinusoidal endothelial cellsHepatol Res20011930632411251313 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="84494" pm="."><plain>51MillerAMWangHParkOHoriguchiNLafdilFMukhopadhyayPMohAFuXYKunosGPacherPAnti-inflammatory and anti-apoptotic roles of endothelial cell STAT3 in alcoholic liver injuryAlcohol Clin Exp Res20103471972520102572 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="84495" pm="."><plain>52BajtayZJózsiMBánkiZThielSThielensNErdeiAMannan-binding lectin and C1q bind to distinct structures and exert differential effects on macrophagesEur J Immunol2000301706171310898508 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="84496" pm="."><plain>53RoychowdhurySMcMullenMRPritchardMTHiseAGvan RooijenNMedofMEStavitskyABNagyLEAn early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in miceHepatology2009491326133419133650 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="84497" pm="."><plain>54DuffieldJSForbesSJConstandinouCMClaySPartolinaMVuthooriSWuSLangRIredaleJPSelective depletion of macrophages reveals distinct, opposing roles during liver injury and repairJ Clin Invest2005115566515630444 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="84498" pm="."><plain>55FallowfieldJAMizunoMKendallTJConstandinouCMBenyonRCDuffieldJSIredaleJPScar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosisJ Immunol20071785288529517404313 </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="84499" pm="."><plain>56NietoNOxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cellsHepatology2006441487150117133487 </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="84500" pm="."><plain>57Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren Campagne MCRIg: a macrophage complement receptor required for phagocytosis of circulating pathogensCell200612491592716530040 </plain></SENT>
</text></ref><ref id="B58"><text><SENT sid="84501" pm="."><plain>58HinglaisNKazatchkineMDMandetCAppayMDBarietyJHuman liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. </plain></SENT>
<SENT sid="84502" pm="."><plain>An immunohistochemical studyLab Invest1989615095142478758 </plain></SENT>
</text></ref><ref id="B59"><text><SENT sid="84503" pm="."><plain>59KumarVAliSRKonradSZwirnerJVerbeekJSSchmidtREGessnerJECell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in miceJ Clin Invest200611651252016453025 </plain></SENT>
</text></ref><ref id="B60"><text><SENT sid="84504" pm="."><plain>60SchieferdeckerHLRothermelETimmermannAGötzeOJungermannKAnaphylatoxin C5a receptor mRNA is strongly expressed in Kupffer and stellate cells and weakly in sinusoidal endothelial cells but not in hepatocytes of normal rat liverFEBS Lett19974063053099136907 </plain></SENT>
</text></ref><ref id="B61"><text><SENT sid="84505" pm="."><plain>61SchlafGSchmitzMHeineIDembergTSchieferdeckerHLGötzeOUpregulation of fibronectin but not of entactin, collagen IV and smooth muscle actin by anaphylatoxin C5a in rat hepatic stellate cellsHistol Histopathol2004191165117415375759 </plain></SENT>
</text></ref><ref id="B62"><text><SENT sid="84506" pm="."><plain>62GuoSPZhangWFGongJPResearch advance in the origin and immunological function of kupffer cellsSheng Li Ke Xue Jin Zhan201647576027424408 </plain></SENT>
</text></ref><ref id="B63"><text><SENT sid="84507" pm="."><plain>63EnomotoNIkejimaKYamashinaSHiroseMShimizuHKitamuraTTakeiYSato AndNThurmanRGKupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxinAlcohol Clin Exp Res20012551S54S11410742 </plain></SENT>
</text></ref><ref id="B64"><text><SENT sid="84508" pm="."><plain>64WheelerMDThurmanRGUp-regulation of CD14 in liver caused by acute ethanol involves oxidant-dependent AP-1 pathwayJ Biol Chem20032788435844112482856 </plain></SENT>
</text></ref><ref id="B65"><text><SENT sid="84509" pm="."><plain>65SchieferdeckerHLSchlafGJungermannKGötzeOFunctions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cellsInt Immunopharmacol2001146948111367531 </plain></SENT>
</text></ref><ref id="B66"><text><SENT sid="84510" pm="."><plain>66ReidDTReyesJLMcDonaldBAVoTReimerRAEksteenBKupffer Cells Undergo Fundamental Changes during the Development of Experimental NASH and Are Critical in Initiating Liver Damage and InflammationPLoS One201611e015952427454866 </plain></SENT>
</text></ref><ref id="B67"><text><SENT sid="84511" pm="."><plain>67BarataLMiwaTSatoSKimDMohammedISongWCDeletion of Crry and DAF on murine platelets stimulates thrombopoiesis and increases factor H-dependent resistance of peripheral platelets to complement attackJ Immunol20131902886289523390291 </plain></SENT>
</text></ref><ref id="B68"><text><SENT sid="84512" pm="."><plain>68LaskowskiJRennerBLe QuintrecMPanzerSHannanJPLjubanovicDRusevaMMBorzaDBAntonioliAHPickeringMCDistinct roles for the complement regulators factor H and Crry in protection of the kidney from injuryKidney Int20169010912227165610 </plain></SENT>
</text></ref><ref id="B69"><text><SENT sid="84513" pm="."><plain>69LiuFWuLWuGWangCZhangLTomlinsonSQinXTargeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in miceAtherosclerosis201423423724324685815 </plain></SENT>
</text></ref><ref id="B70"><text><SENT sid="84514" pm="."><plain>70VernonKARusevaMMCookHTBottoMMalikTHPickeringMCPartial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic MicroangiopathyJ Am Soc Nephrol2016271334134226374608 </plain></SENT>
</text></ref><ref id="B71"><text><SENT sid="84515" pm="."><plain>71Medjeral-ThomasNPickeringMCThe complement factor H-related proteinsImmunol Rev201627419120127782332 </plain></SENT>
</text></ref><ref id="B72"><text><SENT sid="84516" pm="."><plain>72FaberCWilliamsJJuelHBGreenwoodJNissenMHMossSEComplement factor H deficiency results in decreased neuroretinal expression of Cd59a in aged miceInvest Ophthalmol Vis Sci2012536324633022918646 </plain></SENT>
</text></ref><ref id="B73"><text><SENT sid="84517" pm="."><plain>73WilsonVDarlayRWongWWoodKMMcFarlaneJSchejbelLSchmidtIMHarrisCLTellezJHunzeEMGenotype/phenotype correlations in complement factor H deficiency arising from uniparental isodisomyAm J Kidney Dis20136297898323870792 </plain></SENT>
</text></ref><ref id="B74"><text><SENT sid="84518" pm="."><plain>74SchejbelLSchmidtIMKirchhoffMAndersenCBMarquartHVZipfelPGarredPComplement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutationGenes Immun201112909921270828 </plain></SENT>
</text></ref><ref id="B75"><text><SENT sid="84519" pm="."><plain>75BlackallDPMarquesMBHemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generationAm J Clin Pathol2004121 SupplS81S8815298153 </plain></SENT>
</text></ref><ref id="B76"><text><SENT sid="84520" pm="."><plain>76McCulloughRLMcMullenMRSheehanMMPoulsenKLRoychowdhurySChiangDJPritchardMTCaballeriaJNagyLEComplement Factor D protects mice from ethanol-induced inflammation and liver injuryAm J Physiol Gastrointest Liver Physiol2018315G66G7929597356 </plain></SENT>
</text></ref><ref id="B77"><text><SENT sid="84521" pm="."><plain>77WuGHuWShahsafaeiASongWDobarroMSukhovaGKBronsonRRShiGPRotherRPHalperinJAComplement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complexCirc Res200910455055819131645 </plain></SENT>
</text></ref><ref id="B78"><text><SENT sid="84522" pm="."><plain>78WickhamSEHotzeEMFarrandAJPolekhinaGNeroTLTomlinsonSParkerMWTwetenRKMapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9J Biol Chem2011286209522096221507937 </plain></SENT>
</text></ref><ref id="B79"><text><SENT sid="84523" pm="."><plain>79HuangYFedarovichATomlinsonSDaviesCCrystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complexActa Crystallogr D Biol Crystallogr20076371472117505110 </plain></SENT>
</text></ref><ref id="B80"><text><SENT sid="84524" pm="."><plain>80PodackERMüller-EberhardHJBinding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement componentsJ Immunol197812110251030690431 </plain></SENT>
</text></ref><ref id="B81"><text><SENT sid="84525" pm="."><plain>81McDonaldJFNelsestuenGLPotent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerizationBiochemistry199736746474739200695 </plain></SENT>
</text></ref><ref id="B82"><text><SENT sid="84526" pm="."><plain>82ChuQLiuXXiangYLiuQWStudy on the structure and function of complement C3Zhongguo Mianyixue Zazhi201430549553 </plain></SENT>
</text></ref><ref id="B83"><text><SENT sid="84527" pm="."><plain>83LiuQXingGComplement regulatory proteins and IgA nephropathyZhongguo Shiyong Yike201340122124 </plain></SENT>
</text></ref><ref id="B84"><text><SENT sid="84528" pm="."><plain>84de HaasCJVeldkampKEPeschelAWeerkampFVan WamelWJHeeziusECPoppelierMJVan KesselKPvan StrijpJAChemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agentJ Exp Med200419968769514993252 </plain></SENT>
</text></ref><ref id="B85"><text><SENT sid="84529" pm="."><plain>85FujitaEFarkasICampbellWBaranyiLOkadaHOkadaNInactivation of C5a anaphylatoxin by a peptide that is complementary to a region of C5aJ Immunol20041726382638715128829 </plain></SENT>
</text></ref><ref id="B86"><text><SENT sid="84530" pm="."><plain>86GuoRFWardPARole of C5a in inflammatory responsesAnnu Rev Immunol20052382185215771587 </plain></SENT>
</text></ref><ref id="B87"><text><SENT sid="84531" pm="."><plain>87NikiforovichGVBaranskiTJStructural models for the complex of chemotaxis inhibitory protein of Staphylococcus aureus with the C5a receptorBiochem Biophys Res Commun200939048148419799858 </plain></SENT>
</text></ref><ref id="B88"><text><SENT sid="84532" pm="."><plain>88OttoMHawlischHMonkPNMüllerMKlosAKarpCLKöhlJC5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonismJ Biol Chem200427914215114570896 </plain></SENT>
</text></ref><ref id="B89"><text><SENT sid="84533" pm="."><plain>89LiBSCuiSHLvFLChenYLiYCHuCXChenCYProtective effects of complementary peptide of anaphylatoxin C5a on lung injury of experimental sepsis mouseDisan Junyi Daxue Xuebao2006284 </plain></SENT>
</text></ref><ref id="B90"><text><SENT sid="84534" pm="."><plain>90WuZLvFLvCWuYZBlocking effects of anti-sense peptide of C5a on the adhesion between pulmonary vascular endothelial cell and neutrophilZhongduo Mianyixue Zazhi2003195 </plain></SENT>
</text></ref><ref id="B91"><text><SENT sid="84535" pm="."><plain>91LiLChenLZangJTangXLiuYZhangJBaiLYinQLuYChengJC3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney diseaseMetabolism20156459761025682062 </plain></SENT>
</text></ref><ref id="B92"><text><SENT sid="84536" pm="."><plain>92LeeJHKimHKoJLeeYInteraction of C5 protein with RNA aptamers selected by SELEXNucleic Acids Res2002305360536812490703 </plain></SENT>
</text></ref><ref id="B93"><text><SENT sid="84537" pm="."><plain>93BieseckerGDihelLEnneyKBendeleRADerivation of RNA aptamer inhibitors of human complement C5Immunopharmacology19994221923010408383 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
